Research programme: ophthalmologic gene therapy - Adverum/RegeneronAlternative Names: AVA 311
Latest Information Update: 08 Mar 2017
At a glance
- Originator Avalanche Biotechnologies; Regeneron Pharmaceuticals
- Developer Adverum Biotechnologies; Regeneron Pharmaceuticals
- Class Gene therapies
- Mechanism of Action Gene transference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Retinoschisis